CagriSema for Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
The trial aims to test the safety and tolerability of switching from semaglutide to a new treatment called CagriSema for type 2 diabetes. Participants will receive CagriSema, a potential new drug, once a week for about six months. The trial tests three different doses, depending on the previous semaglutide treatment. This trial may suit someone with type 2 diabetes who has maintained a stable weekly dose of semaglutide for at least 90 days and is not using other diabetes medications. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to the development of a promising new treatment.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that CagriSema, a combination of semaglutide and cagrilintide, is generally safe for people with type 2 diabetes. In earlier studies, no treatment-related deaths were reported, and participants experienced significant health improvements. CagriSema also proved more effective for weight loss than semaglutide alone.
The treatment has been tested in several studies, including one 32-week study with 92 participants. These studies consistently demonstrated that CagriSema significantly lowers HbA1c levels, which is crucial for managing diabetes. Overall, the evidence suggests that CagriSema is safe for people with type 2 diabetes, with no major safety issues identified in the studies.12345Why are researchers excited about this trial's treatments?
Researchers are excited about CagriSema for type 2 diabetes because it combines two active ingredients, semaglutide and cagrilintide, offering a potentially powerful treatment option. Unlike most treatments that focus solely on blood sugar control, CagriSema may also help with weight management, thanks to its dual action. While standard treatments like metformin or insulin primarily manage glucose levels, CagriSema targets both glucose and weight, which could lead to better overall health outcomes for patients.
What evidence suggests that CagriSema might be an effective treatment for type 2 diabetes?
Research shows that CagriSema, a combination of cagrilintide and semaglutide, helps manage type 2 diabetes. Studies have found that this treatment can lead to significant weight loss and better blood sugar control. Specifically, one study revealed that participants lost an average of 12.4% of their body weight, surpassing the results of another treatment, tirzepatide. Additionally, CagriSema demonstrated important improvements in blood sugar control. These findings suggest that CagriSema could be a promising option for people with type 2 diabetes seeking to improve their health. Participants in this trial will receive different doses of CagriSema to evaluate its effectiveness and safety.678910
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
This trial is for people with type 2 diabetes who are currently taking semaglutide and want to see how they tolerate switching to a new medication called CagriSema. Participants should meet basic health requirements set by the study team.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants switch from semaglutide to CagriSema and are monitored for safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CagriSema
Trial Overview
The study tests what happens when people with type 2 diabetes switch from their current medicine, semaglutide, to a new treatment called CagriSema. Everyone in the trial will receive CagriSema for about 6 months.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.
Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen
Citations
Efficacy-of-CagriSema-for-Reaching-Anthropometric- ...
in participants who received CagriSema 2.4 mg/2.4 mg, this Page 4 9320 corresponded to 61.3% Versus 28.6%, respectively (Figure 3).
2.
markets.ft.com
markets.ft.com/data/announce/detail?dockey=1330-1001273769en-4EFI3F9EDF4C4UHLKF3NHE9U81Novo's CagriSema delivers superior weight loss versus ...
CagriSema 1.0 mg/1.0 mg achieved superior weight loss of 12.4%* versus tirzepatide 5 mg of 9.1%* and non-inferior HbA1c reduction at week 60 ...
CagriSema
Overall, the combination of cagrilintide and semaglutide was well tolerated, exhibited a positive effect in body weight reduction and ...
4.
stocktitan.net
stocktitan.net/news/NVO/novo-s-cagri-sema-delivers-superior-weight-loss-versus-tirzepatide-luzc9kpilblh.htmlNovo Nordisk CagriSema trial shows 12.4% weight loss
CagriSema 1.0 mg/1.0 mg achieved 12.4% weight loss versus 9.1% with tirzepatide 5 mg at week 60 in adults with type 2 diabetes in the REIMAGINE ...
5.
sciencehub.novonordisk.com
sciencehub.novonordisk.com/content/dam/sciencehub/global/en/congresses-and-scientific-publications/scientific-publications/articles/0/37364590/documents/frias-cagri-sema-ms-synopsis-slides.pdfSynopsis of the original article of primary CagriSema data
In people with T2D, treatment with CagriSema resulted in clinically relevant improvements in glycaemic control (including CGM parameters).
6.
thecardiologyadvisor.com
thecardiologyadvisor.com/news/cagrisema-elicits-significant-weight-loss-in-obesity-with-or-without-t2d/CagriSema Elicits Significant Weight Loss in Obesity With ...
CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.
7.
sciencehub.novonordisk.com
sciencehub.novonordisk.com/scientific-publications/articles/original-article.37364590.efficacy-and-safety-of-co-administered.htmlEfficacy and safety of co-administered once-weekly ...
No fatal adverse events were reported. INTERPRETATION: In people with type 2 diabetes, treatment with CagriSema resulted in clinically relevant improvements in ...
Novo Nordisk files for FDA approval of CagriSema, the first ...
In addition, a supportive secondary analysis showed that about half (54%) of trial participants with obesity at baseline treated with CagriSema ...
NCT06388187 | A Research Study to See How Well ...
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo ...
CagriSema for Type 2 Diabetes and Obesity
In a 32-week trial with 92 participants, the combination of semaglutide and cagrilintide (CagriSema) led to a significant reduction in HbA1c levels compared to ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.